This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development, including the efficacy and potential availability of rivaroxaban to reduce the risk of major adverse cardiac events for certain patient populations. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
*** Individual results will vary. Regarding the endorsements and testimonials provided on this website, please note that while they represent individual, real life experiences of women who have used Amberen, they are individual results and may not reflect the typical results that other users will experience. We do not make any claims or assurances that these individual experiences represent the typical results that Amberen consumers will achieve. See * above for information regarding typical results as shown in clinical trials. Video testimonials were compensated for their participation. Read more These endorsements and testimonials are provided as a means for customers to share their experiences using Amberen with other women, and are not provided or intended to be interpreted as claims that Amberen will provide the same benefits to all customers. The endorsements and testimonials are displayed verbatim except where edited for privacy reasons, length or to correct grammatical or typing errors, and not all endorsements or testimonials are shown in their entirety as privacy concerns, space availability and relevancy at times require minor editing prior to being displayed. Endorsements and testimonials are never edited, however, in a way that would change their substantive meaning or essence.
The caudal approach to the epidural space involves the use of a Tuohy needle, an intravenous catheter, or a hypodermic needle to puncture the sacrococcygeal membrane . Injecting local anaesthetic at this level can result in analgesia and/or anaesthesia of the perineum and groin areas. The caudal epidural technique is often used in infants and children undergoing surgery involving the groin, pelvis or lower extremities. In this population, caudal epidural analgesia is usually combined with general anaesthesia since most children do not tolerate surgery when regional anaesthesia is employed as the sole modality.